Mirodenafil for the Treatment of Erectile Dysfunction: A Systematic Review of the Literature

被引：14

作者：

Park, Hyun Jun ^{[1
]}

Moon, Kyung Hyun ^{[2
]}

Lee, Seung Wook ^{[3
]}

Lee, Won Ki ^{[4
]}

Kam, Sung Chul ^{[5
]}

Lee, Jun Ho ^{[6
]}

Park, Nam Cheol ^{[1
]}

机构：

[1] Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Med Res Inst,Dept Urol, Busan, South Korea

[2] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Urol, Ulsan, South Korea

[3] Hanyang Univ, Guri Hosp, Dept Urol, Guri, South Korea

[4] Hallym Univ, Coll Med, Chuncheon Sacred Heart Hosp, Dept Urol, Chunchon, South Korea

[5] Gyeongsang Natl Univ, Sch Med, Dept Urol, Jinju, South Korea

[6] Natl Police Hosp, Dept Urol, Seoul, South Korea

来源：

WORLD JOURNAL OF MENS HEALTH | 2014年 / 32卷 / 01期

关键词：

Erectile dysfunction; Phosphodiesterase; 5; inhibitors; Review; Treatment efficacy;

D O I：

10.5534/wjmh.2014.32.1.18

中图分类号：

R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

摘要：

Phosphodiesterase type 5 (PDE5) inhibitors are the most commonly used treatment for erectile dysfunction (ED). Since the launch of sildenafil, several drugs-including mirodenafil, sildenafil citrate (sildenafil), tadalafil, vardenafil HCL (vardenafil), udenafil, and avanafil-have become available. Mirodenafil is a newly developed pyrrolopyrimidinone compound, which is a potent, reversible, and selective oral PDE5 inhibitor. Mirodenafil was launched in Korea in 2007, and an orally disintegrating film of mirodenafil was developed in 2011 for benefitting patients having difficulty in swallowing tablets. This study aimed to review the pharmacokinetic characteristic profile of mirodenafil and report evidence on its efficacy in the case of ED. In addition, we reviewed randomized controlled studies of mirodenafil's daily administration and efficacy for lower urinary tract symptoms.

引用

页码：18 / 27

页数：10

共 55 条

[1] Impact of Tadalafil Once Daily in Men With Erectile Dysfunction-Including a Report of the Partners' Evaluation [J].